

Documenting Sex and Sex Differences in Animal Studies

Anne Rigby¹ Gregory Y. H. Lip^{2,3} Christian Weber^{1,4,5}

¹Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany

²Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom

³Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark

⁴German Centre for Cardiovascular Research (DZHK), Partner site Munich Heart Alliance, Munich, Germany

⁵Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands

Address for correspondence Anne Rigby, PhD, Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Bayern 80336, Germany (e-mail: Anne.Rigby@med.uni-muenchen.de).

Christian Weber, MD, Institute for Cardiovascular Prevention (IPEK), LMU Munich, Pettenkofersstraße 9, 80336 Munich, Germany (e-mail: chweber@med.lmu.de).

Thromb Haemost 2020;120:879–882.

The National Institutes of Health reports that women now represent nearly half of all participants in clinical research (<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102.html>). At *Thrombosis and Haemostasis*, we have indeed published several clinical articles, specifically highlighting the effects of gender differences in recent years.^{1–12} In contrast, basic and preclinical studies are more often and at times traditionally conducted in male animals. This can lead to an underappreciation of sex differences and their influence in health and disease, despite sex being not only an important experimental variable but also a notable factor determining cardiovascular outcomes, for example, stroke risk in atrial fibrillation, as well as platelet function and antiplatelet therapy in women.^{3,4,6,11–14} Hence, we would like to follow the good example implemented by the Arteriosclerosis, Thrombosis, and Vascular Biology Council^{15,16} and commit ourselves to regularly monitoring sex and sex differences in animal studies published in *Thrombosis and Haemostasis*. This report should help elaborating an editorial approach regarding the requirements for documenting sex when conducting animal studies to be submitted to our journal.

In our first survey, we counted 59 articles reporting animal studies in *Thrombosis and Haemostasis* spanning 2018 and 2019.^{17–75} All studies, except two, were conducted in mice or rats. The two other studies used either rabbits or nonhuman primates. Mice represented the vast majority (86%) of animals used. One article studied mouse embryos and was not included. Out of the remaining 58 articles, 52% reported sex consistently, 38% did not report sex at all, while 10% reported sex albeit not for all animals used (► **Fig. 1**).

Among the studies documenting sex, 53% used male animals only, 14% of studies reported females only, whereas 33% included both male and female animals, albeit not necessarily for all experiments (► **Fig. 2**). None of the articles studying one sex only provided a justification for it. Out of the articles investigating both sexes, less than half of the studies ($N = 5$) set out to compare results in both sexes. The other studies either pooled data from both sexes or used one or another sex depending on the experiment without providing justification for this. One study only provided justification for pooling data of both sexes together.

This first analysis clearly warrants adjusting our editorial process to improve documentation and justifications of sex and sex differences in animal studies published in the journal as an incentive to improve the potential mechanistic and/or clinical relevance of the results. As a consequence, we have decided that future publications will require systematic documentation of the sex used in preclinical studies with immediate effect. We should strive to control that this consistently applies to all animals used in each study. We indeed noted that 10% of studies reported sex for one mouse background or one species but not for other backgrounds/species within the same study. We should also demand and control convincing explanation for studying only one sex, from either the scientific literature, preliminary data, or other relevant considerations. None of the articles analyzed here provided such a justification. Thus, the Editors should encourage preclinical studies to include both sexes, and presenting data distinctly for each sex to potentially identify sex differences wherever possible. Pooled data was only briefly justified in one article analyzed

received
March 25, 2020
accepted
March 25, 2020


© 2020 Georg Thieme Verlag KG
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0040-1710017>.
ISSN 0340-6245.



Sex reported consistently N (%)	Sex reported inconsistently N (%)	Sex not reported N (%)
30 (52%)	6 (10%)	22 (38%)

Fig. 1 Reporting sex in animal studies published in *Thrombosis and Haemostasis* in 2018–2019. The Pie Chart shows the percentage of manuscripts not reporting sex (grey slice), reporting sex in animal studies consistently (dark blue slice) and inconsistently (light blue slice).



Male N (%)	Female N (%)	Male and female N (%)
19 (53%)	5 (14%)	12 (33%)

Fig. 2 Sex used for animal studies published in *Thrombosis and Haemostasis* in 2018–2019 when documented. The Pie Chart shows the percentage of manuscripts using male and female (grey slice), male only (dark blue slice) and female only (light blue slice).

here. Pooling data of both sexes together should only be permitted when results do not reveal significant differences between male and female animals.

In conclusion, we will accordingly modify our submission guidelines and request authors to report sex and study both sexes whenever possible to ensure that this important aspect is no longer ignored. We are not only confident this should improve transparency and reproducibility of data published in our journal, but expect this new incentive to provide important cues to understand sex influences on cardiovascular homeostasis and disease.

Conflict of Interest

G.Y.H.L. reports consultancy and speaker fees from Bayer, Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo outside the submitted work. No fees received personally.

References

- 1 Fiechter M, Haider A, Bengs S, et al. Sex differences in the association between inflammation and ischemic heart disease. *Thromb Haemost* 2019;119(09):1471–1480
- 2 Gencer B, Mach F. Gender specificity and interpretation of functional cardiac imaging: let’s talk about sex. *Thromb Haemost* 2019;119(09):1379–1381
- 3 Overvad TF, Rasmussen LH, Skjøth F, et al. Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. *Thromb Haemost* 2014;112(04):789–795
- 4 Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. *Thromb Haemost* 2014;111(03):385–391
- 5 Zöller B, Li X, Ohlsson H, Sundquist J, Sundquist K. Age- and sex-specific seasonal variation of venous thromboembolism in patients with and without family history: a nationwide family study in Sweden. *Thromb Haemost* 2013;110(06):1164–1171
- 6 Gross L, Kupka D, Trenk D, et al. Gender and outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: the TROPICAL-ACS Gender Substudy. *Thromb Haemost* 2019;119(09):1527–1538
- 7 Schmitt C, Charoin-Pannier A, McIntyre C, et al. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age. *Thromb Haemost* 2012;108(01):54–64
- 8 Bauersachs RM, Riess H, Hach-Wunderle V, et al. Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis. *Thromb Haemost* 2010;103(04):710–717

- 9 Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. *Thromb Haemost* 2010;104(03):471–484
- 10 Lapostolle F, Le Toumelin P, Chassery C, et al. Gender as a risk factor for pulmonary embolism after air travel. *Thromb Haemost* 2009;102(06):1165–1168
- 11 Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. *Thromb Haemost* 2009;101(05):938–942
- 12 Lane DA, Lip GYH. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. *Thromb Haemost* 2009;101(05):802–805
- 13 Patti G, De Caterina R, Abbate R, et al; Working Group on Thrombosis of the Italian Society of Cardiology. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. *Eur Heart J* 2014;35(33):2213–23b
- 14 Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. *QJM* 2014;107(12):955–967
- 15 Lu HS, Schmidt AM, Hegele RA, et al. Reporting sex and sex differences in preclinical studies. *Arterioscler Thromb Vasc Biol* 2018;38(10):e171–e184
- 16 Lu HS, Schmidt AM, Hegele RA, et al. Annual report on sex in preclinical studies: *Arteriosclerosis, Thrombosis, and Vascular Biology* publications in 2018. *Arterioscler Thromb Vasc Biol* 2020;40(01):e1–e9
- 17 Andraska EA, Luke CE, Elflin MA, et al. Pre-clinical model to study recurrent venous thrombosis in the inferior vena cava. *Thromb Haemost* 2018;118(06):1048–1057
- 18 Biasin V, Wygrecka M, Bärnthaler T, et al. Docking of mepri α to heparan sulphate protects the endothelium from inflammatory cell extravasation. *Thromb Haemost* 2018;118(10):1790–1802
- 19 Chen X, Wu W, Wang S, et al. Magnetic targeting improves the therapeutic efficacy of microbubble-mediated obstructive thrombus sonothrombolysis. *Thromb Haemost* 2019;119(11):1752–1766
- 20 Chiang C-Y, Chien C-Y, Qiou W-Y, et al. Genetic depletion of thromboxane A₂/thromboxane-prostanoid receptor signalling prevents microvascular dysfunction in ischaemia/reperfusion injury. *Thromb Haemost* 2018;118(11):1982–1996
- 21 Chorawala MR, Prakash P, Doddapattar P, Jain M, Dhanesha N, Chauhan AK. Deletion of extra domain A of fibronectin reduces acute myocardial ischaemia/reperfusion injury in hyperlipidaemic mice by limiting thrombo-inflammation. *Thromb Haemost* 2018;118(08):1450–1460
- 22 Cooke EJ, Zhou JY, Wyseure T, et al. Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice. *Thromb Haemost* 2018;118(06):1036–1047
- 23 de Porto APNA, Claushuis TAM, van der Donk LEH, et al. Platelet Btk is required for maintaining lung vascular integrity during murine pneumococcal pneumosepsis. *Thromb Haemost* 2019;119(06):930–940
- 24 Decouture B, Becker P-H, Therond P, Gaussem P, Bachelot-Loza C. Evidence that MRP4 is only partly involved in S1P secretion during platelet activation. *Thromb Haemost* 2018;118(06):1116–1118
- 25 Diehl P, Nienaber F, Zaldivia MTK, et al. Lysophosphatidylcholine is a major component of platelet microvesicles promoting platelet activation and reporting atherosclerotic plaque instability. *Thromb Haemost* 2019;119(08):1295–1310
- 26 Elzoheiry M, Da'dara AA, deLaforcade AM, El-Beshbishi SN, Skelly PJ. The essential ectoenzyme SmNPP5 from the human intravascular parasite *Schistosoma mansoni* is an ADPase and a potent inhibitor of platelet aggregation. *Thromb Haemost* 2018;118(06):979–989
- 27 Feng Y, Yu M, Zhu F, Zhang S, Ding P, Wang M. IL-9 Promotes the development of deep venous thrombosis by facilitating platelet function. *Thromb Haemost* 2018;118(11):1885–1894
- 28 Feuerborn R, Besser M, Potì F, et al. Elevating endogenous sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein receptor-deficient (LDL-R^{-/-}) mice. *Thromb Haemost* 2018;118(08):1470–1480
- 29 Gebhard C, Maafi F, Stähli BE, et al. Beneficial effects of high-density lipoproteins on acquired von Willebrand syndrome in aortic valve stenosis. *Thromb Haemost* 2018;118(02):288–297
- 30 Ghebouli R, Loyau S, Maire M, et al. Amino-fucoidan as a vector for rtPA-induced fibrinolysis in experimental thrombotic events. *Thromb Haemost* 2018;118(01):42–53
- 31 Glise L, Larsson P, Jern S, et al. Disturbed laminar blood flow causes impaired fibrinolysis and endothelial fibrin deposition in vivo. *Thromb Haemost* 2019;119(02):223–233
- 32 Guillamat Prats R, Rami M, Ring L, et al. Deficiency of monoacylglycerol lipase enhances IgM plasma levels and limits atherogenesis in a CB2-dependent manner. *Thromb Haemost* 2019;119(02):348–351
- 33 Hamadi A, Grigg AP, Dobie G, et al. Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. *Thromb Haemost* 2019;119(07):1112–1123
- 34 Hardy AT, Palma-Barqueros V, Watson SK, et al. Significant hyporesponsiveness to GPVI and CLEC-2 agonists in pre-term and full-term neonatal platelets and following immune thrombocytopenia. *Thromb Haemost* 2018;118(06):1009–1020
- 35 Horowitz JC, Tschumperlin DJ, Kim KK, et al. Urokinase plasminogen activator overexpression reverses established lung fibrosis. *Thromb Haemost* 2019;119(12):1968–1980
- 36 Hsu C-C, Hsu R-B, Ohniwa RL, et al. Neutrophil extracellular traps enhance *Staphylococcus aureus* vegetation formation through interaction with platelets in infective endocarditis. *Thromb Haemost* 2019;119(05):786–796
- 37 Huang S-W, Lien J-C, Kuo S-C, Huang TF. Inhibitory effects of an orally active thromboxane A₂ receptor antagonist, nstppb5185, on atherosclerosis in ApoE-deficient mice. *Thromb Haemost* 2018;118(02):401–414
- 38 Jing Y, Hu Y, Li H, et al. Assessment of thrombotic risk in atrial fibrillation with ultrasound molecular imaging of P-selectin. *Thromb Haemost* 2018;118(02):388–400
- 39 Jourdi G, Gouin-Thibault I, Siguret V, Gandrille S, Gaussem P, Le Bonniec B. FXa- α 2-macroglobulin complex neutralizes direct oral anticoagulants targeting FXa in vitro and in vivo. *Thromb Haemost* 2018;118(09):1535–1544
- 40 Kashiwagi H, Yuhki KI, Imamichi Y, et al. Prostaglandin F₂ α facilitates platelet activation by acting on prostaglandin E₂ receptor subtype EP3 and thromboxane A₂ receptor TP in mice. *Thromb Haemost* 2019;119(08):1311–1320
- 41 Kim K, Chang Y-K, Bian Y, Bae ON, Lim KM, Chung JH. Procoagulant and pro-thrombotic effects of paclitaxel mediated by red blood cells. *Thromb Haemost* 2018;118(10):1765–1775
- 42 Kojima M, Ozawa N, Mori Y, et al. Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. *Thromb Haemost* 2018;118(01):182–194
- 43 Kölmel S, Hobohm L, Käberich A, et al. Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension. *Thromb Haemost* 2019;119(08):1332–1346
- 44 Kral-Pointner JB, Schrottmaier WC, Salzmann M, et al. Platelet PI3K modulates innate leukocyte extravasation during acid-induced acute lung inflammation. *Thromb Haemost* 2019;119(10):1642–1654
- 45 Kurano M, Tsuneyama K, Morimoto Y, et al. Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury. *Thromb Haemost* 2018;118(06):1021–1035

- 46 Le Quellec S, Dane AP, Barbon E, et al. Recombinant adeno-associated viral vectors expressing human coagulation FIX-E456H variant in hemophilia B mice. *Thromb Haemost* 2019; 119(12):1956–1967
- 47 Le Quellec S, Enjolras N, Perot E, Girard J, Negrier C, Dargaud Y. Fusion of factor IX to factor XIII-B sub-unit improves the pharmacokinetic profile of factor IX. *Thromb Haemost* 2018; 118(12): 2053–2063
- 48 Lee W, Park S-Y, Yoo Y, et al. Macrophagic stabilin-1 restored disruption of vascular integrity caused by sepsis. *Thromb Haemost* 2018; 118(10):1776–1789
- 49 Li G, Wang S, Li N, et al. Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopenia. *Thromb Haemost* 2018; 118(10):1752–1764
- 50 Li X, Wang SW, Feng Q, et al. Novel murine model of immune thrombocytopenia through immunized CD41 knockout mice. *Thromb Haemost* 2019; 119(03):377–383
- 51 Luo Q, Wei G, Wang X, et al. All-trans retinoic acid impairs platelet function and thrombus formation and inhibits protein kinase C β / δ phosphorylation. *Thromb Haemost* 2019; 119(10):1655–1664
- 52 Ma Y-H, Huang C-W, Wen C-J, Lu YC, Wey SP, Wun TC. Passivating injured endothelium with kinexins in thrombolytic therapy. *Thromb Haemost* 2018; 118(01):90–102
- 53 Magisetty J, Pendurthi UR, Madhunapantula SV, Grandoni J, Rao LVM. Increased accumulation and retention of rhFVIIa (eptacog beta) in knee joints of hemophilia A mice compared to wild-type mice. *Thromb Haemost* 2019; 119(08):1283–1294
- 54 Martos L, Ramón LA, Oto J, et al. α 2-macroglobulin is a significant in vivo inhibitor of activated protein C and low APC: α 2M levels are associated with venous thromboembolism. *Thromb Haemost* 2018; 118(04):630–638
- 55 Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, et al. Chondroitin sulphate attenuates atherosclerosis in ApoE knockout mice involving cellular regulation of the inflammatory response. *Thromb Haemost* 2018; 118(07):1329–1339
- 56 Muczynski V, Verhenne S, Casari C, et al. A thrombin-activatable factor X variant corrects hemostasis in a mouse model for hemophilia A. *Thromb Haemost* 2019; 119(12):1981–1993
- 57 Nicolaou A, Northoff BH, Zhao Z, et al. The ADAM17 metalloproteinase maintains arterial elasticity. *Thromb Haemost* 2018; 118(01):210–213
- 58 Peng S, Xue G, Chen S, et al. tPA point mutation at autolysis loop enhances resistance to PAI-1 inhibition and catalytic activity. *Thromb Haemost* 2019; 119(01):77–86
- 59 Rautou P-E, Busse J, Kheloufi M, et al. Endothelial autophagy does not influence venous thrombosis in mice. *Thromb Haemost* 2018; 118(06):1113–1115
- 60 Sauter RJ, Sauter M, Obrich M, et al. Anaphylatoxin receptor C3aR contributes to platelet function, thrombus formation and in vivo haemostasis. *Thromb Haemost* 2019; 119(01):179–182
- 61 Scanlon VM, Teixeira AM, Tyagi T, et al. Epithelial (E)-cadherin is a novel mediator of platelet aggregation and clot stability. *Thromb Haemost* 2019; 119(05):744–757
- 62 Shaya SA, Gani DM, Weitz JI, Kim PY, Gross PL. Factor XIII prevents pulmonary emboli in mice by stabilizing deep vein thrombi. *Thromb Haemost* 2019; 119(06):992–999
- 63 Stocker TJ, Pircher J, Skenderi A, et al. The actin regulator coronin-1A modulates platelet shape change and consolidates arterial thrombosis. *Thromb Haemost* 2018; 118(12):2098–2111
- 64 Thomassen S, Mastenbroek TG, Swieringa F, et al. Suppressive role of tissue factor pathway inhibitor- α in platelet-dependent fibrin formation under flow is restricted to low procoagulant strength. *Thromb Haemost* 2018; 118(03):502–513
- 65 Tovar AMF, Vairo BC, Oliveira SMCG, et al. Converting the distinct heparins sourced from bovine or porcine mucosa into a single anticoagulant drug. *Thromb Haemost* 2019; 119(04):618–632
- 66 Trabold K, Makhoul S, Gambaryan S, van Ryn J, Walter U, Jurk K. The direct thrombin inhibitors dabigatran and lepirudin inhibit GPIIb α -mediated platelet aggregation. *Thromb Haemost* 2019; 119(06):916–929
- 67 Troullinaki M, Garcia-Martin R, Sprott D, et al. 53BP1 deficiency promotes pathological neovascularization in proliferative retinopathy. *Thromb Haemost* 2019; 119(03):439–448
- 68 Tseng C-N, Chang Y-T, Yen C-Y, et al. Early inhibition of P-selectin/P-selectin glycoprotein ligand-1 reduces intimal hyperplasia in murine vein grafts through platelet adhesion. *Thromb Haemost* 2019; 119(12):2014–2024
- 69 Urisono Y, Sakata A, Matsui H, et al. Von Willebrand factor aggravates hepatic ischemia-reperfusion injury by promoting neutrophil recruitment in mice. *Thromb Haemost* 2018; 118(04):700–708
- 70 Viola JR, Lemnitzer P, Paulin N, et al. Deletion of MFG8 inhibits neointima formation upon arterial damage. *Thromb Haemost* 2018; 118(07):1340–1342
- 71 Vogt K, Mahajan-Thakur S, Wolf R, et al. Release of platelet-derived sphingosine-1-phosphate involves multidrug resistance protein 4 (MRP4/ABCC4) and is inhibited by statins. *Thromb Haemost* 2018; 118(01):132–142
- 72 Wang X, Pan B, Hashimoto Y, et al. Defibrotide stimulates angiogenesis and protects endothelial cells from calcineurin inhibitor-induced apoptosis via upregulation of AKT/Bcl-xL. *Thromb Haemost* 2018; 118(01):161–173
- 73 Yakovlev S, Cao C, Galisteo R, Zhang L, Strickland DK, Medved L. Fibrin-VLDL receptor-dependent pathway promotes leukocyte transmigration by inhibiting Src kinase Fyn and is a target for fibrin β 15–42 peptide. *Thromb Haemost* 2019; 119(11):1816–1826
- 74 Yao X, Chen W, Liu J, et al. Deep vein thrombosis is modulated by inflammation regulated via sirtuin 1/NF- κ B signalling pathway in a rat model. *Thromb Haemost* 2019; 119(03):421–430
- 75 Zhao X-M, Wang Y, Yu Y, et al. Plasma phospholipid transfer protein promotes platelet aggregation. *Thromb Haemost* 2018; 118(12):2086–2097